Most nasal lymphomas in these populations are of NK-cell lineage ... The role of autologous and allogeneic hematopoietic stem-cell transplantation should be established by controlled trials.

Troculeucel is an autologous NK cell therapy, which means it is derived from a patient's own immune cells and expanded ...

While it’s also possible to make an autologous patient-specific therapy from NK cells, Shingleton doesn’t see that idea taking off. “Beating the efficacy of CAR-T would be tough,” he says.

In addition, autologous cell transplantation is not ... development efforts have focused on safe and effective allogeneic NK cell transfusion procedures, in which a patient receives cells from ...

Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative ...

The partners will use Cellino's autonomous biomanufacturing tech to produce high-quality autologous iPSCs for Karis' ...

About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of ...

With a bone marrow transplant, the stem cells are taken from the bone marrow. With a stem cell transplant, the stem cells are taken from either the bone marrow or the bloodstream. There are 2 main ...

About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of ...

Most nasal lymphomas in these populations are of NK-cell lineage ... The role of autologous and allogeneic hematopoietic stem-cell transplantation should be established by controlled trials.

March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen” or the "Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative ...